Good News for Patients with Strep

SEPTEMBER 01, 2006
Susan Farley

The Amoxicillin PULSYS Phase III Trial achieved its clinical goals in the treatment of adults and adolescents with pharyngitis/tonsillitis due to Group A streptococcal infections (strep throat). Advancis Pharmaceutical Corp enrolled 620 adults and adolescents in a randomized, double-blind, multicenter, noninferiority trial in November 2005. Researchers compared the once-daily, 775-mg tablet of Amoxicillin PULSYS for 10 days with 250 mg of penicillin VK 4 times a day for 10 days. The primary desired end point of the trial was bacterial eradication at the "test-of-cure" visit for patients who had completed the protocol, measured by throat cultures before and after treatment. Bacterial eradication at the posttherapy test-of-cure visit among the patients who had completed the protocol was 85% in the Amoxicillin PULSYS group and 83.4% with penicillin. Stan L. Block, MD, an investigator in the study and a professor of clinical pediatrics noted, "The outcomes were achieved through a single-daily-dose administration, a significant factor with the potential to positively impact patient compliance."

Ms. Farley is a freelance medical writer based in Wakefield, RI.




SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.